Rosato-Siri Marcelo D, Zambello Erika, Mutinelli Chiara, Garbati Nicoletta, Benedetti Roberto, Aldegheri Laura, Graziani Francesca, Virginio Caterina, Alvaro Giuseppe, Large Charles H
Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.).
Autifony s.r.l., Verona, Italy (M.D.R.-S., G.A.); Aptuit s.r.l., Verona, Italy (E.Z., C.M., N.G., R.B., L.A., C.V.); Medicines Research Centre, GlaxoSmithKline S.p.A., Verona, Italy (F.G.); and Autifony Therapeutics Limited, Imperial College Incubator, London, United Kingdom (C.H.L.)
J Pharmacol Exp Ther. 2015 Sep;354(3):251-60. doi: 10.1124/jpet.115.225748. Epub 2015 Jun 17.
Kv3.1 and Kv3.2 high voltage-activated potassium channels, which display fast activation and deactivation kinetics, are known to make a crucial contribution to the fast-spiking phenotype of certain neurons. Pharmacological experiments show that the blockade of native Kv3 currents with low concentrations of tetraethylammonium or 4-aminopyridine impairs the expression of this firing phenotype. In particular, Kv3 channels are highly expressed by fast-spiking, parvalbumin-positive interneurons in corticolimbic brain circuits, which modulate the synchronization of cortical circuits and the generation of brain rhythms. Here, we describe a novel small molecule, (5R)-5-ethyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-2,4-imidazolidinedione (AUT1), which modulates Kv3.1 and Kv3.2 channels in human recombinant and rodent native neurons. AUT1 increased whole currents mediated by human Kv3.1b and Kv3.2a channels, with a concomitant leftward shift in the voltage dependence of activation. A less potent effect was observed on hKv3.3 currents. In mouse somatosensory cortex slices in vitro, AUT1 rescued the fast-spiking phenotype of parvalbumin-positive-fast-spiking interneurons following an impairment of their firing capacity by blocking a proportion of Kv3 channels with a low concentration of tetraethylammonium. Notably, AUT1 had no effect on interneuron firing when applied alone. Together, these data confirm the role played by Kv3 channels in the regulation of the firing phenotype of somatosensory interneurons and suggest that AUT1 and other Kv3 modulators could represent a new and promising therapeutic approach to the treatment of disorders associated with dysfunction of inhibitory feedback in corticolimbic circuits, such as schizophrenia.
Kv3.1和Kv3.2高电压激活钾通道具有快速激活和失活动力学,已知对某些神经元的快速放电表型起关键作用。药理学实验表明,用低浓度四乙铵或4-氨基吡啶阻断天然Kv3电流会损害这种放电表型的表达。特别是,Kv3通道在皮质边缘脑回路中快速放电、小白蛋白阳性的中间神经元中高度表达,这些中间神经元调节皮质回路的同步性和脑节律的产生。在此,我们描述了一种新型小分子(5R)-5-乙基-3-(6-{[4-甲基-3-(甲氧基)phenyl]氧基}-3-吡啶基)-2,4-咪唑啉二酮(AUT1),它可调节人重组神经元和啮齿动物天然神经元中的Kv3.1和Kv3.2通道。AUT1增加了由人Kv3.1b和Kv3.2a通道介导的全电流,同时激活的电压依赖性向左偏移。在hKv3.3电流上观察到较弱的效应。在体外小鼠体感皮层切片中,AUT1挽救了小白蛋白阳性快速放电中间神经元因用低浓度四乙铵阻断一部分Kv3通道而受损的放电能力后的快速放电表型。值得注意的是,单独应用AUT1对中间神经元放电没有影响。这些数据共同证实了Kv3通道在调节体感中间神经元放电表型中的作用,并表明AUT1和其他Kv3调节剂可能代表一种新的、有前景的治疗方法,用于治疗与皮质边缘回路中抑制性反馈功能障碍相关的疾病,如精神分裂症。